🚀 VC round data is live in beta, check it out!
Sunshine Lake Pharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Sunshine Lake Pharma and similar public comparables like TransThera Sciences, Tarsus Pharmaceuticals, Jilin Aodong, Spyre Therapeutics and more.
Sunshine Lake Pharma Overview
About Sunshine Lake Pharma
Sunshine Lake Pharma Co Ltd is a a vertically integrated pharmaceutical company engaging in research and development, production and commercialization of pharmaceutical products. It strategically focus on therapeutic areas of infectious diseases, chronic diseases and oncology. Its existing anti-infective product portfolio mainly includes (i) its top-selling product, Kewei (oseltamivir phosphate), for the treatment of influenza (in particular, Type A and Type B influenza viruses), (ii) one innovative drug developed in-house, Dongweien (emitasvir phosphate), for the treatment of hepatitis C, and (iii) three generic drugs for the treatment of infections caused by sensitive bacteria, namely Clarithromycin, Levofloxacin and Moxifloxacin Hydrochloride.
Founded
2003
HQ
Employees
6.5K
Website
Sectors
Financials (FY)
EV
$4B
Sunshine Lake Pharma Financials
Sunshine Lake Pharma reported last fiscal year revenue of $583M and EBITDA of $55M.
In the same fiscal year, Sunshine Lake Pharma generated $443M in gross profit, $55M in EBITDA, and $1M in net income.
Sunshine Lake Pharma P&L
In the most recent fiscal year, Sunshine Lake Pharma reported revenue of $583M and EBITDA of $55M.
Sunshine Lake Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $583M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $443M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 76% | XXX | XXX | XXX |
| EBITDA | — | XXX | $55M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 10% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 12% | XXX | XXX | XXX |
| Net Profit | — | XXX | $1M | XXX | XXX | XXX |
| Net Margin | — | XXX | 0% | XXX | XXX | XXX |
| Net Debt | — | — | $374M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Sunshine Lake Pharma Stock Performance
Sunshine Lake Pharma has current market cap of $3B, and enterprise value of $4B.
Market Cap Evolution
Sunshine Lake Pharma's stock price is $5.57.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4B | $3B | 0.0% | XXX | XXX | XXX | $0.00 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSunshine Lake Pharma Valuation Multiples
Sunshine Lake Pharma trades at 6.4x EV/Revenue multiple, and 67.6x EV/EBITDA.
Sunshine Lake Pharma Financial Valuation Multiples
As of March 7, 2026, Sunshine Lake Pharma has market cap of $3B and EV of $4B.
Equity research analysts estimate Sunshine Lake Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Sunshine Lake Pharma has a P/E ratio of 2427.0x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV (current) | $4B | XXX | $4B | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 6.4x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 67.6x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 55.4x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 8.5x | XXX | XXX | XXX |
| P/E | — | XXX | 2427.0x | XXX | XXX | XXX |
| EV/FCF | — | XXX | (34.6x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Sunshine Lake Pharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Sunshine Lake Pharma Margins & Growth Rates
Sunshine Lake Pharma's revenue in the last fiscal year declined by (37%).
Sunshine Lake Pharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (37%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 10% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (83%) | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 19% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 14% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 22% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 65% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Sunshine Lake Pharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| TransThera Sciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Tarsus Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Jilin Aodong | XXX | XXX | XXX | XXX | XXX | XXX |
| Spyre Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Edgewise Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sunshine Lake Pharma M&A Activity
Sunshine Lake Pharma acquired XXX companies to date.
Last acquisition by Sunshine Lake Pharma was on XXXXXXXX, XXXXX. Sunshine Lake Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Sunshine Lake Pharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSunshine Lake Pharma Investment Activity
Sunshine Lake Pharma invested in XXX companies to date.
Sunshine Lake Pharma made its latest investment on XXXXXXXX, XXXXX. Sunshine Lake Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Sunshine Lake Pharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Sunshine Lake Pharma
| When was Sunshine Lake Pharma founded? | Sunshine Lake Pharma was founded in 2003. |
| Where is Sunshine Lake Pharma headquartered? | Sunshine Lake Pharma is headquartered in China. |
| How many employees does Sunshine Lake Pharma have? | As of today, Sunshine Lake Pharma has over 6K employees. |
| Is Sunshine Lake Pharma publicly listed? | Yes, Sunshine Lake Pharma is a public company listed on HKEX. |
| What is the stock symbol of Sunshine Lake Pharma? | Sunshine Lake Pharma trades under 06887 ticker. |
| When did Sunshine Lake Pharma go public? | Sunshine Lake Pharma went public in 2025. |
| Who are competitors of Sunshine Lake Pharma? | Sunshine Lake Pharma main competitors are TransThera Sciences, Tarsus Pharmaceuticals, Jilin Aodong, Spyre Therapeutics. |
| What is the current market cap of Sunshine Lake Pharma? | Sunshine Lake Pharma's current market cap is $3B. |
| What is the current revenue of Sunshine Lake Pharma? | Sunshine Lake Pharma's last fiscal year revenue is $583M. |
| What is the current EV/Revenue multiple of Sunshine Lake Pharma? | Current revenue multiple of Sunshine Lake Pharma is 6.4x. |
| Is Sunshine Lake Pharma profitable? | No, Sunshine Lake Pharma is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.